KBPH Kyto BioPharma Inc. featured news, full reports, and detailed charts
Kyto BioPharma Inc. (KBPH/KBPH.OB) Wrap Up:
Kyto BioPharma, Inc., a biopharmaceutical company, acquires and develops toxic and non-immunosuppressive proprietary drugs for the treatment of cancer, arthritis, and other proliferate and autoimmune diseases primarily in the United States. The company involves in developing receptor-mediated technologies to control the uptake of vitamin B12 by non-controlled proliferate cells. Its research and product development programs include bioconjugates technology, which creates a molecular complex through the non-covalent binding of a transportable state of the drug with the vitamin B12; growth blockers that are used to deplete the tumors of the vitamin B12, an essential co-factor for the biosynthes...www.kytobiopharma.com
Founded in 1999
Kyto BioPharma Inc. (KBPH:OTC Bulletin Board Market)
LAST $1.50 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of October 27, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Kyto BioPharma Inc. (KBPH)
|
OPEN
--
|
PREVIOUS CLOSE
$1.50
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
06/23/09 - $1.70
|
52 WEEK LOW
10/22/09 - $0.70
|
|
|
MARKET CAP
19.1M
|
AVERAGE VOLUME 3 mo
0.0
|
|
|
DILUTED EPS TTM
$-0.03
|
SHARES OUTSTANDING
12.7M
|
|
|
KBPH Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
KBPH Top Compensated Officers
No compensation data is available at this time for the top officers at this company.
Executives, Board Directors
Key developments for Kyto BioPharma Inc. (KBPH)
Donald MacAdam Resigns Kyto BioPharma Inc. as a Director
07/6/2009
Effective June 29, 2009, Donald MacAdam has resigned as a Director of Kyto BioPharma Inc.
Kyto BioPharma Inc. Auditor Raises 'Going Concern' Doubt
06/29/2009
Kyto BioPharma Inc. filed its 10-K on June 29, 2009 for the period ending March 31, 2009. In this report its auditor, Jewett, Schwartz, Wolfe & Associates, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Kyto BioPharma Inc. Auditor Raises 'Going Concern' Doubt
07/1/2008
Kyto BioPharma Inc. filed its 10KSB on July 01, 2008 for the period ending March 31, 2008. In this report its auditor, Jewett, Schwartz, Wolfe & Associates, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
KBPH Competitors
| Company | Last | Change |
| Bioxel Pharma Inc | $0.0001 USD | 0.00 |
| Bristol Myers Squibb Co | $24.46 USD | +0.43 |
| Cell Therapeutics Inc | $1.08 USD | -0.03 |
| Enzon Pharmaceuticals Inc | $10.32 USD | -0.07 |
| Mylan Inc | $17.55 USD | +0.12 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | KBPH | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
KBPH |
||
|
KBPH transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Kyto BioPharma Inc.
Would you like to leave a comment about Kyto BioPharma Inc. KBPH/KBPH.OB
Find out what social network information about Kyto BioPharma Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Kyto BioPharma Inc. there is more great information available at Realpennies.com